Evolving Consensus

diagnosis and management of TGCT is changing

Growing awareness of the ways that TGCT can wreck patients' lives has led to shifts in the thinking about diagnosis and treatment.

RECENT DEVELOPMENTS IN MANAGING TGCT

Diagnosis and decision-making

MRI and needle biopsy are recommended for diagnosis and to guide a comprehensive treatment decision-making process. Active surveillance may be an appropriate option for asymptomatic patients.¹

Treatment with resection

Surgical resection may be the preferred TGCT treatment option for some patients, especially for localized TGCT. The potential risks and benefits should be discussed between the multidisciplinary care team and the patient.^1,2

Systemic treatment

Systemic treatment should be considered when evaluating what may be most appropriate for your patient.¹ However, in a recent study of patients with TGCT, only about 20% discussed systemic therapy with their HCP at initial diagnosis³

Treatment with radiotherapy

The consensus remains that radiotherapy is not recommended as it comes with a potential risk of malignant transformation and low efficacy¹

Post-treatment surveillance

MRI-based surveillance is recommended after surgery or systemic treatment to monitor response to therapy and detect recurrence early¹

PEER COLLABORATION AND KNOWLEDGE SHARING

Keeping referring physicians informed and being a source of thought leadership on managing TGCT can help to optimize peer-to-peer referrals and patient care.

Peer collaboration and knowledge sharing

Some ways medical oncologists can optimize collaboration in peer-to-peer referrals:

Keep referring physicians informed about a patient’s progress on TGCT treatment and any complications
Be a source of thought leadership on managing TGCT and advances in the treatment landscape
Address TGCT with urgency once patients are referred to you

SIGN UP FOR MORE INFORMATION ABOUT TGCT

Get the latest updates from EMD Serono

STAY INFORMED

UP NEXT

LEARN MORE ABOUT

THE CURRENT TREATMENT LANDSCAPE

REFERENCES

1. Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. doi:10.1016/j.ctrv.2022.102491 2. Palmerini E, Staals EL, Maki RG, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer. 2015;51(2):210-217. doi:10.1016/j.ejca.2014.11.001 3. Stern S, McKenzie PF, Bernthal N, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510. doi:10.1080/14796694.2025.2488635

EMD Serono is a Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.

200 Pier 4 Blvd, Boston, MA 02210

This website is intended only for residents of the United States. Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

US-NONOTGCT-00007 10/25

diagnosis and management of TGCT is changing

RECENT DEVELOPMENTS IN MANAGING TGCT

Diagnosis and decision-making

Treatment with resection

Systemic treatment

Treatment with radiotherapy

Post-treatment surveillance

PEER COLLABORATION AND KNOWLEDGE SHARING

Peer collaboration and knowledge sharing

SIGN UP FOR MORE INFORMATION ABOUT TGCT

SIGN UP FOR MORE INFORMATION ABOUT TGCT

THIS SITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS

Peer collaboration and knowledge sharing